MA53438A - Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées - Google Patents

Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées

Info

Publication number
MA53438A
MA53438A MA053438A MA53438A MA53438A MA 53438 A MA53438 A MA 53438A MA 053438 A MA053438 A MA 053438A MA 53438 A MA53438 A MA 53438A MA 53438 A MA53438 A MA 53438A
Authority
MA
Morocco
Prior art keywords
dendritic cells
extracellular vesicles
targeting dendritic
targeting
vesicles
Prior art date
Application number
MA053438A
Other languages
English (en)
Inventor
Dalia Burzyn
Kevin Dooley
Shelly Ann Martin
Raymond J Moniz
Nikki Ross
Sriram Sathyanarayanan
Ke Xu
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/048026 external-priority patent/WO2019040920A1/fr
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MA53438A publication Critical patent/MA53438A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053438A 2018-08-24 2019-08-23 Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées MA53438A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2018/048026 WO2019040920A1 (fr) 2017-08-25 2018-08-24 Préparation d'exosomes thérapeutiques à l'aide de protéines membranaires
US201962870574P 2019-07-03 2019-07-03

Publications (1)

Publication Number Publication Date
MA53438A true MA53438A (fr) 2021-09-15

Family

ID=69591350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053438A MA53438A (fr) 2018-08-24 2019-08-23 Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées

Country Status (5)

Country Link
US (1) US20230181758A1 (fr)
EP (1) EP3841112A1 (fr)
MA (1) MA53438A (fr)
TW (1) TW202024120A (fr)
WO (1) WO2020041720A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286603B (zh) * 2018-11-16 2025-07-22 隆萨销售股份公司 工程化的细胞外囊泡及其用途
US20220323519A1 (en) * 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
WO2020247432A1 (fr) * 2019-06-04 2020-12-10 Thomas Jefferson University Vésicules extracellulaires dérivées d'oligodendrocytes pour la thérapie de la sclérose en plaques
EP4009989A4 (fr) * 2019-08-06 2023-08-23 Ohio State Innovation Foundation Vésicules extracellulaires thérapeutiques
WO2021237100A1 (fr) * 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Procédés d'administration ciblée de vésicules extracellulaires dans le poumon
CN112675298B (zh) * 2020-12-28 2024-05-03 中国医学科学院医学生物学研究所 一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用
CA3226019A1 (fr) 2021-07-20 2023-01-26 Ags Therapeutics Sas Vesicules extracellulaires provenant de microalgues, leur preparation et leurs utilisations
WO2023144127A1 (fr) 2022-01-31 2023-08-03 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations
WO2023232976A1 (fr) 2022-06-03 2023-12-07 Ags Therapeutics Sas Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations
US20260007610A1 (en) * 2022-07-13 2026-01-08 Mdimune Inc. Cell-derived vesicles engineered with anchor proteins and use thereof
EP4608424A1 (fr) 2022-10-24 2025-09-03 AGS Therapeutics SAS Vésicules extracellulaires provenant de microalgues, leur biodistribution lors d'une administration intranasale, et leurs utilisations
KR20250110348A (ko) 2022-11-23 2025-07-18 제이제이알앤디 엘엘씨 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법
WO2025176847A1 (fr) 2024-02-21 2025-08-28 Ags Therapeutics Sas Administration oculaire d'agents actifs par l'intermédiaire de vésicules extracellulaires de microalgues

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
GB0805159D0 (en) 2008-03-19 2008-04-23 Sancho Madrid David Immune modulation via C-type lectin
CN101970491A (zh) 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 树突状细胞标记物及其用途
WO2009030996A1 (fr) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Composés triazole utilisés comme agonistes du récepteur de type toll (tlr)
WO2009088401A2 (fr) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Combinaisons immunostimulantes de ligands tlr et leurs procédés d'utilisation
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
US20120039806A1 (en) * 2009-03-23 2012-02-16 Mireille Hanna Lahoud Compounds and Methods for Modulating an Immune Response
CA2777198C (fr) 2009-10-06 2018-07-24 Panacela Labs, Inc. Utilisation de recepteur de type toll et agoniste pour le traitement du cancer
CA2813494A1 (fr) 2009-10-08 2011-04-14 President And Fellows Of Harvard College Procedes et compositions pour l'amelioration d'une maladie auto-immune utilisant des proteines de fusion d'un anticorps anti-recepteurs des cellules dendritiques avec des sequences peptidiques
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
WO2013053008A2 (fr) 2011-10-14 2013-04-18 The Walter And Eliza Hall Institute Of Medical Research Molécules liant clec9a
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (fr) 2013-05-03 2020-07-08 The Regents of The University of California Induction de dinucléotide cyclique de l'interféron de type i
WO2014189806A1 (fr) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons »
ME03586B (fr) 2013-05-18 2020-07-20 Univ California Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (fr) 2013-11-19 2017-08-16 The University of Chicago Utilisation d'un agoniste de sting en tant que traitement anti-cancéreux
WO2015185565A1 (fr) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Di-nucléotides cycliques utilisés comme modulateurs de sting
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
UY36969A (es) 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
MX2020001790A (es) 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.

Also Published As

Publication number Publication date
TW202024120A (zh) 2020-07-01
WO2020041720A1 (fr) 2020-02-27
US20230181758A1 (en) 2023-06-15
EP3841112A1 (fr) 2021-06-30

Similar Documents

Publication Publication Date Title
MA49971A (fr) Vésicules extracellulaires modifiées et leurs utilisations
EP3615046A4 (fr) Cellules exprimant des récepteurs d'activation chimériques et des récepteurs de stimulation chimériques et utilisations associées
IL259470A (en) Neural cell extracellular vessicles
EP3807321A4 (fr) Constructions anti-mésothéline et utilisations associées
CO2020004233A2 (es) Vesículas extracelulares bacterianas
HRP20260306T1 (hr) Sredstva za poboljšanje stanične transfekcije i/ili proizvodnje raav vektora
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
EP3612030A4 (fr) Inhibiteurs d'indole ahr et leurs utilisations
IL250042A0 (en) Expanded tracking and advertising targeting of social networking users
EP3380117A4 (fr) Cellules génétiquement modifiées et utilisations de ces dernières
EP3781196C0 (fr) Ciblage de cellule in vivo spécifique à une séquence
EP3362075A4 (fr) Cellules tueuses naturelles et cellules ilc3, et leurs utilisations
EP2882847A4 (fr) Cellules tueuses naturelles et leurs utilisations
EP4009989A4 (fr) Vésicules extracellulaires thérapeutiques
EP3710020A4 (fr) Cellules immunoréactives sécrétant l'il-36 et utilisations associées
EP3532605A4 (fr) Génération améliorée de cellules de lignée musculaire et leurs utilisations thérapeutiques
EP3307874A4 (fr) Dérivation de cellules souches hépatiques et types de cellules hépatiques ainsi qu'utilisations associées
EP3445381A4 (fr) Production d'aav dans des cellules d'insectes, méthodes et compositions associées
EP3313873A4 (fr) Constructions ciblant des complexes peptide ny-eso-1/cmh et leurs utilisations
EP3443506C0 (fr) Neurone artificiel
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
MX364714B (es) Animales no humanos geneticamente modificados y metodos de uso de los mismos.
UY34539A (es) Heteroarilos y usos de los mismos
EP3796895A4 (fr) Vésicules extracellulaires et leurs utilisations